Abstract mTOR [mammalian (or mechanistic) target of rapamycin] is a protein kinase that, as part of mTORC1 (mTOR complex 1), acts as a critical molecular link between growth signals and the processes underlying cell growth. Although there has been intense interest in the upstream mechanisms regulating mTORC1, the full repertoire of downstream molecular events through which mTORC1 signalling promotes cell growth is only recently coming to light. It is now recognized that mTORC1 promotes cell growth and proliferation in large part through the activation of key anabolic processes. Through a variety of downstream targets, mTORC1 alters cellular metabolism to drive the biosynthesis of building blocks and macromolecules fundamentally essential for cell growth, including proteins, lipids and nucleic acids. In the present review, we focus on the metabolic functions of mTORC1 as they relate to the control of cell growth and proliferation. As mTORC1 is aberrantly activated in a number of tumour syndromes and up to 80 % of human cancers, we also discuss the importance of this mTORC1-driven biosynthetic programme in tumour growth and progression.
Introduction
The metabolism of all cells, from bacteria to humans, is profoundly different between resting and growing states. A resting cell, such as a naive immune cell or that of a terminally differentiated tissue, is metabolically focused on producing ATP through catabolic processes to fuel the maintenance of energy-costly homoeostatic processes, such as cytoskeletal functions and ion and nutrient transport. With few exceptions, it is believed that the resting cell acquires any needed building blocks (e.g. lipids and nucleotides) for low-level macromolecular synthesis from exogenous sources. In contrast, a cell induced to grow (i.e. increase in size by taking on mass) or proliferate (i.e. increase in number through cell division) undergoes a metabolic shift towards anabolic processes for the de novo synthesis of macromolecules from available nutrients [1] . In order for such regulated reprogramming of metabolism to occur, there must be molecular links between the pathways sensing cellular growth signals and those controlling the key metabolic networks underlying cell growth.
mTORC1 {mTOR [mammalian (or mechanistic) target of rapamycin] complex 1} has emerged as a major signalling node through which cells co-ordinate growth signals with control over the major anabolic processes required for cell growth. There have been many reviews on upstream Key words: carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydro-orotase (CAD), mammalian target of rapamycin complex 1 (mTORC1), pentose phosphate pathway, sterol-regulatory-element-binding protein (SREBP), tumour metabolism. Abbreviations used: CAD, carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydro-orotase; 4E-BP, eukaryotic initiation factor 4E-binding protein; eIF, eukaryotic initiation factor; ER, endoplasmic reticulum; HIF1α, hypoxia-inducible factor 1α; mTOR, mammalian (or mechanistic) target of rapamycin; mTORC1, mTOR complex 1; PPP, pentose phosphate pathway; S6K, ribosomal S6 kinase; SREBP, sterol-regulatory-element-binding protein; 5 -TOP, 5 -terminal oligopyrimidine tract. 1 To whom correspondence should be addressed (email bmanning@hsph.harvard.edu).
regulation of mTORC1 by physiological and pathological growth conditions [2] [3] [4] . In the present review, we discuss the downstream metabolic consequences of mTORC1 activation, with a focus on mechanisms promoting the macromolecular synthesis of proteins, lipids and nucleic acids to drive cell growth and proliferation (Figure 1 ).
Protein synthesis
Protein synthesis is a fundamental, but energy-costly, biosynthetic process essential for cell growth. A major sensor of cellular energy status, mTORC1 has long been appreciated as a critical regulator of protein synthesis and exerts control of the pathway through distinct downstream targets (reviewed in [3, 5] ). mTORC1 acutely stimulates the translation initiation of a subset of mRNAs through phosphorylation of the 4E-BPs (eukaryotic initiation factor 4E-binding proteins). 4E-BP phosphorylation weakens its inhibitory interaction with eIF (eukaryotic initiation factor) 4E, and allows assembly of the eIF4F translation initiation complex, thereby enhancing cap-dependent translation (reviewed in [5] ). Additionally, mTORC1 phosphorylates and activates the ribosomal S6 kinases (S6K1 and S6K2), which phosphorylate multiple components of the translation machinery, including ribosomal protein S6, eIF4B and eEF2k (eukaryotic elongation factor 2 kinase) [6, 7] . However, the ultimate effects of these regulatory events are unclear, as the loss of S6K isoforms seems to have little effect on global translation, or the translation of specific subclasses of mRNA [8] [9] [10] [11] .
Whereas mTORC1 signalling exerts acute effects on mRNA translation, its activation leads to longer-term effects on the protein synthetic capacity of the cell, in large part through its promotion of ribosome biogenesis. mTORC1 has long been known to promote the translation of a class of mRNAs with 5 -TOPs (5 -terminal oligopyrimidine tracts), which encode nearly all ribosomal proteins and translation elongation factors [12, 13] . Thoreen et al. [14] have shown recently that the mTORC1-dependent phosphorylation of 4E-BP1/2 is responsible for the translational activation of 5 -TOP mRNAs. This highlights an additional role for mTORC1 in promoting synthesis of the translation machinery, including ribosomes, which comprise four different rRNAs and nearly 80 ribosomal proteins. In addition to enhancing the translation of these ribosomal proteins, there is evidence that mTORC1 signalling promotes the transcription of rRNAs [15, 16] . Furthermore, through unknown mechanisms, S6K appears to regulate the transcription of a specific set of genes encoding nucleolar proteins involved in the regulation of ribosome biogenesis, the so-called RiBi transcriptional programme, which affects rRNA synthesis and maturation [9] .
Lipid synthesis
Along with protein, there is an increased demand for lipids in growing cells, and proliferating cells must double their lipid membrane content with each cell cycle. mTORC1 has emerged as a major promoter of de novo lipid synthesis in both growing cells and specialized lipid-producing cells, such as liver and adipose [18] . Although the exact molecular mechanism is currently unknown, mTORC1 stimulates lipogenesis through the activation of SREBP (sterol-regulatory-element-binding protein) 1 and 2 [19, 20] . The SREBPs are transcription factors that are responsible for the induction of genes encoding most lipogenic enzymes involved in the synthesis of both fatty acids and sterols [21] [22] [23] . They are synthesized as transmembrane residents of the ER (endoplasmic reticulum) where, upon sterol depletion, they are transported to the Golgi apparatus and cleaved sequentially by two membrane-associated sitespecific proteases [24] . This releases the transcriptionally active N-terminus of SREBP for translocation to the nucleus and induction of gene promoters containing sterol-response elements. In addition to its control by ER-associated sterols, mTORC1 signalling stimulates the processing of SREBP [18] . S6K1, downstream of mTORC1, has been found to be required for the processing of SREBP in mouse embryonic fibroblasts and in the liver, where the bulk of de novo lipid synthesis occurs [19, [25] [26] [27] [28] . In addition, Lipin1, a phosphatidic acid phosphatase that is directly inhibited by mTORC1 via multisite phosphorylation, negatively regulates SREBP accumulation in the nucleus [29] . The existence of these, and perhaps other, mechanisms downstream of mTORC1 for the control of the SREBPs emphasizes their role as critical effectors for mTORC1 signalling. Cells with activated mTORC1 signalling display elevated de novo lipid synthesis that is dependent on the activation of these transcription factors, which are also required for cell growth and proliferation in such settings [19, 20] .
Nucleotide synthesis
To support an increased demand for RNA and DNA, growing and proliferating cells require a large abundance of nucleotides [30] . A major metabolic pathway required for nucleotide synthesis is the PPP (pentose phosphate pathway), which is the sole source of de novo synthesized ribose. Ribose 5-phosphate is the product of two distinct branches of the PPP: the irreversible oxidative branch, which through the oxidation of glucose 6-phosphate also generates reducing equivalents in the form of NADPH, and the non-oxidative branch, a series of reversible reactions generating ribose from glycolytic intermediates. In experiments measuring the effects of mTORC1 activation and inhibition on relative flux through these two branches, it was found that mTORC1 preferentially stimulates flux through the oxidative branch Through transcriptional mechanisms, mTORC1 induces the expression of genes encoding enzymes of the PPP, and preferentially stimulates flux through the oxidative branch. This promotes production of NADPH, as well as phosphoribosyl pyrophosphate, required for the synthesis of purine and pyrimidine nucleotides. In parallel, mTORC1 specifically and acutely stimulates flux through the de novo pyrimidine synthesis pathway via S6K1-dependent phosphorylation of Ser 1859 on CAD, a multifunctional enzyme that catalyses the first three steps in the pathway. Thus growth signals (e.g. growth factors and nutrients) stimulate an mTORC1-dependent increase in de novo synthesized nucleotides, and their incorporation into RNA and DNA. OMP, orotidine monophosphate; UMPS, UMP synthase.
[19]. This occurs predominantly through the transcriptional induction of genes encoding PPP enzymes, which is driven, at least in part, by SREBP1. Through this regulation, mTORC1 promotes not only the production of ribose 5-phosphate, which can be used in the synthesis of purine and pyrimidine nucleotides, but also the production of NADPH, providing essential reducing power to drive the anabolic processes of lipid and nucleotide synthesis (Figure 2 ). Whereas the synthesis of pyrimidines and purines both require ribose from the PPP, they appear to be otherwise independently regulated. Pyrimidines (e.g. UTP, CTP, dTTP and dCTP) are of vital importance for growing cells, not only as building blocks for RNA and DNA, but also for the synthesis of glycogen (via UDP-glucose), membrane phospholipids (via CDP-choline and CDP-diacylglycerol) and protein glycosylation (via UDP-GlcNAc and UDPglucose) [31] . Cells can obtain pyrimidines through either salvage pathways, requiring the availability and uptake of exogenous nucleosides, or through de novo synthesis from glutamine, aspartate and bicarbonate. Although it is generally accepted that salvage pathways are sufficient to sustain the demands of quiescent terminally differentiated cells, growing and proliferating cells require activation of the de novo synthesis pathway [32, 33] . In addition to its role in promoting the production of ribose, recent studies have demonstrated that mTORC1 signalling acutely stimulates de novo pyrimidine synthesis through a mechanism independent of its transcriptional regulation of the PPP [34, 35] . This occurs through the S6K1-dependent phosphorylation of CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydro-orotase), a multifunctional enzyme that catalyses the first three steps in pyrimidine synthesis. In response to mTORC1 signalling, S6K1 directly phosphorylates CAD on Ser 1859 within a conserved linker region between the aspartate transcarbamylase and dihydroorotase domains [31, 36, 37] (Figure 2 ). Acute stimulation of mTORC1 by growth factors or amino acids results in increased flux through this biosynthetic pathway and increased incorporation of de novo synthesized pyrimidines into DNA and RNA, including rRNA. Importantly, these effects were sensitive to treatment with either rapamycin or an S6K1-specific inhibitor. As more than half of the ribosomal mass is RNA, this molecular link between mTORC1 signalling and the stimulation of de novo nucleotide synthesis serves to facilitate not only the DNA synthesis essential for dividing cells, but also the robust synthesis of new ribosomes, a hallmark of growing cells. Interestingly, elevated de novo purine synthesis has also been reported in rapidly proliferating cells; however, the mechanism of this regulation has not been determined [38] .
Linking cancer genetics to cancer metabolism through mTORC1
Although above we focus on the anabolic growth-stimulatory effects of mTOR, it is important to note that, in normal cells, mTOR activity is tightly regulated, both temporally and spatially, so that it is only transiently activated by physiological growth signals (e.g. following a meal). This regulation is critical for cellular, tissue-specific and organismal homoeostasis. However, an early event in the transformation of normal cells to cancer cells is to disconnect growth-promoting pathways from their dependence on physiological signals. It is not surprising, then, that mTOR is aberrantly activated in up to 80 % of human cancers, across nearly all lineages, and underlies the development of a variety of tumour syndromes, including tuberous sclerosis complex and lymphangioleiomyomatosis [2] .
One of the hallmarks of cancer cells is their altered metabolic state. Like normal cells induced to proliferate, such as during an immune response, cancer cells reprogramme their metabolism from a homoeostatic state, where nutrient catabolism or storage prevails, to an anabolic state driving the conversion of nutrients into biomass [39] . The anabolic programme of cancer cells is supported by increased uptake of glucose and its preferential consumption by glycolysis to lactate, rather than the predominant oxidation of glucose in the mitochondria seen in normal cells. This fermentation of glucose even in the presence of oxygen, referred to as aerobic glycolysis or the Warburg effect, is believed to support anabolic metabolism by supplying a steady stream of glycolytic intermediates that can be used in the synthesis of ribose for nucleotide synthesis, glycerol for phospholipid synthesis and amino acids for protein synthesis [1] . Interestingly, in addition to inducing expression of the enzymes of lipid synthesis and the PPP, mTORC1 signalling has also been found to increase expression of the primary glucose transporter (Glut1) and most of the enzymes of glycolysis [19, 40] . The induction of these genes downstream of mTORC1 requires HIF1α (hypoxiainducible factor 1α), and results in a HIF1α-dependent increase in glucose uptake and metabolic flux through glycolysis. This transcription factor is rapidly degraded under normal oxygen concentrations, but can accumulate in settings with elevated mTORC1 signalling through a mechanism involving its increased translation downstream of the 4E-BP-eIF4E branch. Therefore, along with the key biosynthetic processes described above, mTORC1 is one of many factors that can contribute to the glycolytic switch featured in most cancer cells.
Another frequently observed metabolic property of cancer cells is the up-regulation of de novo lipid synthesis, which is reflected in elevated levels of lipogenic enzymes [41] . Whereas the role of mTORC1 activation in promoting the lipogenic programme of cancer cells has yet to be established, inhibition of the mTORC1 effector SREBP1 or its transcriptional targets stearoyl-CoA desaturase, fatty acid synthase, ATP citrate lyase or acetyl-CoA carboxylase has been found to adversely affect a variety of cancer models [42] [43] [44] [45] [46] [47] . Currently, the lipid content and dependencies of cancer cells are poorly understood, as is the relative importance of exogenous lipids, including those obtained from dietary sources or mobilized from the liver and adipose, compared with the tumour cell intrinsic synthesis of lipids. This is especially true within a growing tumour, as very little is known regarding the availability of exogenous lipids within the tumour microenvironment. However, the de novo production of mono-unsaturated fatty acids appears to be a strict requirement for proliferating cancer cells, probably because of their abundance in membrane phospholipids [42, 45, 47] . The balance between saturated and unsaturated fatty acids has been shown to be particularly important in the ER, where excessive amounts of saturated lipids result in ER stress and the production of reactive oxygen species, which can ultimately induce apoptosis [44, [47] [48] [49] . Like unsaturated fatty acids, cholesterol is a critical membrane lipid that might also be particularly important in cancer cells, possibly due to its requirement in lipid rafts, where survival signalling can originate [50] . In support of this notion, correlative studies have found that cancer patients taking statins exhibit prolonged survival, but a role for statins in treating cancer remains uncertain [51, 52] . Furthermore, the importance of mTORC1 and SREBP isoforms in the synthesis of specific membrane, storage and signalling lipids stimulated by oncogenic signalling pathways in cancer cells remains an open and intriguing question.
All proliferating cells, from bacteria to cancer, increase their ribosome content and protein synthesis accordingly [53] [54] [55] [56] . As a convergence point for many oncogenic signalling pathways, mTORC1 activation is likely to be a major driver of the enhanced ribosome biogenesis and protein synthetic capacity of tumour cells. In addition to global up-regulation of the translation machinery required for cell growth and proliferation, mTORC1 signalling through the 4E-BP-eIF4E branch has also been found to promote the translation of mRNAs encoding proteins important for cancer cell survival, invasion and metastasis [57, 58] . Therefore targeting mTORC1 signalling, particularly with the new class of ATPcompetitive inhibitors, which, unlike rapamycin, completely block the regulation of 4E-BP, has the potential to influence both early and late stages of tumour progression [59] .
The importance of de novo nucleotide synthesis in cell growth, proliferation and cancer is well recognized [60] [61] [62] . It has been estimated that cancer cells require ten times more pyrimidines than that which can be supplied exogenously, highlighting the importance of de novo pyrimidine biosynthesis in growing tumours [30] . The recent findings that mTORC1 enhances de novo pyrimidine synthesis through at least two independent mechanisms, suggests that mTORC1 may play a key role in supporting this increased demand for pyrimidines in cancer cells. Indeed, whereas no direct link to mTORC1 has been established, numerous studies have found pyrimidine biosynthesis, as well as CAD expression and activity, to be up-regulated in a variety of tumour-derived cell lines [61, 63, 64] . Furthermore, inhibition of CAD and pyrimidine synthesis decreases tumour cell proliferation, viability and survival [39] . In fact, some of the most widely used chemotherapeutic drugs (e.g. 5-fluorouracil and methotrexate) act by inhibiting pyrimidine synthesis [60] . Importantly, gene amplification or up-regulated expression of CAD is a mechanism of acquired resistance to such compounds [65] . The decrease in metabolic flux through CAD in response to mTOR inhibitors [34, 35] might explain recent findings that mTOR inhibitors can act synergistically with these chemotherapeutic agents [66, 67] . Future work should focus on the therapeutic implications of the mTORC1-mediated effects on nucleotide synthesis. Common oncogenic events lead to constitutive mTORC1 activation, which stimulates metabolic pathways driving the de novo synthesis of macromolecules (proteins, lipids and nucleic acids) allowing tumour cell intrinsic growth and proliferation. As the tumour outgrows its source of nutrients from the vasculature, exogenous supplies of building blocks and macromolecules become limiting, and these mTORC1-driven anabolic changes provide a growth advantage to the tumour cell. mTORC1 signalling also increases the levels of HIF1, which becomes stabilized and increased further by the hypoxic tumour microenvironment. As well as increasing glucose uptake and glycolysis, HIF1 stimulates angiogenesis to restore the supply of nutrients and oxygen to the growing tumour.
It is clear that mTORC1 is a key molecular link between physiological and pathological growth signals and control of the metabolic processes underlying cell growth. It is tempting to speculate that prolonged activation of mTOR signalling triggered by oncogenic events, or perhaps nutrient excess, supports the initiation of tumour development through the co-ordinated up-regulation of de novo synthesis of proteins, lipids and nucleic acids, as well as the metabolic pathways that provide the energy, reducing power and precursors to sustain them. As tumours enlarge, outgrowing their source of nutrients from the vasculature, oxygen and other key nutrients and macromolecules become limiting. The stimulation of cell intrinsic biosynthetic processes, as well as the normoxic activation of HIF1, downstream of mTORC1, is likely to create a metabolic cellular environment that preconditions the cells for this transition. It is also possible that the mTORC1-mediated accumulation of HIF1, before its robust stabilization once the tumour cells experience hypoxia, allows for an earlier onset of angiogenesis to support tumour growth (Figure 3) . With mTOR inhibitors, either alone or in combination with other compounds, currently in over 100 clinical cancer trials, it is critical to further define the oncometabolic effects of mTORC1, with a particular need for understanding its in vivo role within growing tumours. 
